GLP-1 agonists can cause rare but significant skin reactions including hypersensitivity reactions, eosinophilic panniculitis, bullous pemphigoid, and drug eruptions.
Rare but significantSkin reactions to GLP-1 drugs are uncommon but include serious conditions like bullous pemphigoid that require prompt recognition and treatment
What the researchers found
Reported cutaneous reactions to GLP-1 agonists include dermal hypersensitivity reactions, eosinophilic panniculitis, bullous pemphigoid, and morbilliform drug eruptions. These are rare but clinically significant. Diagnosis requires clinical suspicion, thorough medication history, and supporting histopathology when available. Management centers on stopping the GLP-1 drug and tailoring anti-inflammatory or immunomodulatory treatment to the specific reaction type.
Why it matters
Millions of people now take GLP-1 drugs. While skin reactions are rare, clinicians need to recognize them promptly since they can be mistaken for other dermatological conditions. As prescribing expands to weight loss populations, these reactions may become more frequently encountered.
The numbers in context
GLP-1 agonists have demonstrated efficacy in reducing HbA1c, BMI, and cardiovascular events. Cutaneous reactions are rare but significant.
How the study worked
Narrative review of published case reports and case series documenting cutaneous adverse reactions attributed to GLP-1 agonist use.
Who was studied
Published case reports and series of GLP-1 agonist skin reactions
What this study cannot tell us
Based entirely on case reports and case series — the lowest level of clinical evidence. No incidence rates can be calculated. Publication bias likely overrepresents unusual reactions. Cannot establish causation versus coincidence in individual cases.
How to read the evidence
Rated preliminary: narrative review of case reports only. Provides clinical awareness but cannot establish incidence or risk factors.
When this study was published
Published in 2024. Timely given the rapid expansion of GLP-1 drug use for weight loss beyond the diabetes population.
The bigger picture
As GLP-1 drugs move from niche diabetes treatment to mass-market weight loss medication, understanding the full spectrum of adverse reactions — including rare skin reactions — becomes increasingly important for patient safety.
Questions still open
- Are skin reactions more common with specific GLP-1 drugs or routes of administration?
- Can patients who develop skin reactions safely switch to a different GLP-1 agonist?
- Is there a dose-response relationship for cutaneous adverse effects?
Common questions
Can Ozempic or other GLP-1 drugs cause skin problems?
What should I do if I get a skin reaction from a GLP-1 drug?
Read the original research
Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature.
Archives of dermatological research, 316(6), 248
Citation
Salazar, Carlos E; Patil, Mihir K; Aihie, Osaigbokan; Cruz, Nicolas; Nambudiri, Vinod E. (2024). Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature.. Archives of dermatological research, 316(6), 248. https://doi.org/10.1007/s00403-024-02969-3